Clay Siegall Biography and Net Worth

Director of Shattuck Labs

Dr. Clay Siegall is the President, Chief Executive Officer and Chairman of the Board of Immunome, Inc. (Nasdaq: IMNM). With a distinguished career in leadership and drug development, he has significantly contributed to the pharmaceutical industry, including spearheading the establishment of antibody-drug conjugates as a backbone of cancer therapy in many indications. Previously, Dr. Siegall held the positions of Chief Executive Officer, President, and Chairman of the Board at Seagen Inc. (formerly Seattle Genetics, Inc.). He was the founder of Seattle Genetics, established in 1998, where he guided the company to prominence as a pharmaceutical leader, particularly in the development of antibody-drug conjugates for cancer therapy. Prior to founding Seattle Genetics, Dr. Siegall held numerous leadership positions at Bristol Myers Squibb’s Pharmaceutical Research Institute and the National Cancer Institute. Dr. Siegall holds a Ph.D. in Genetics from George Washington University as well as a B.S. in Zoology from the University of Maryland.

What is Clay B. Siegall's net worth?: The estimated net worth of Clay B. Siegall is at least $1.41 million as of June 9th, 2026. Siegall owns 318,608 shares of Shattuck Labs stock worth more than $1,406,654 as of June 16th. This net worth estimate does not reflect any other investments that Siegall may own. Learn More about Clay B. Siegall's net worth.
How do I contact Clay B. Siegall?: The corporate mailing address for Siegall and other Shattuck Labs executives is , , . Shattuck Labs can also be reached via phone at 512-900-4690 and via email at [email protected]. Learn More on Clay B. Siegall's contact information.
Has Clay B. Siegall been buying or selling shares of Shattuck Labs?: Within the last three months, Clay B. Siegall has bought $250,000.00 in Shattuck Labs stock. Most recently, on Tuesday, June 9th, Clay B. Siegall bought 62,500 shares of Shattuck Labs stock. The stock was acquired at an average cost of $4.00 per share, with a total value of $250,000.00. Following the completion of the transaction, the director now directly owns 318,608 shares of the company's stock, valued at $1,274,432. Learn More on Clay B. Siegall's trading history.
Who are Shattuck Labs' active insiders?: Shattuck Labs' insider roster includes Mona Ashiya (Director), Tyler Brous (Director), Josiah Hornblower (Director), Andrew Neill (CFO), Taylor Schreiber (CEO), Abhinav Shukla (Chief Technical Officer), Clay Siegall (Director), and Erin Thomson (General Counsel). Learn More on Shattuck Labs' active insiders.
Are insiders buying or selling shares of Shattuck Labs?: In the last twelve months, Shattuck Labs insiders bought shares 3 times. They purchased a total of 12,674,754 shares worth more than $11,222,660.98. In the last twelve months, insiders at the sold shares 2 times. They sold a total of 32,032 shares worth more than $212,544.32. The most recent insider tranaction occured on June, 9th when Director Clay B Siegall bought 62,500 shares worth more than $250,000.00. Insiders at Shattuck Labs own 8.8% of the company. Learn More about insider trades at Shattuck Labs.
Information on this page was last updated on 6/9/2026.

Clay B. Siegall Insider Trading History at Shattuck Labs

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/9/2026	Buy	62,500	$4.00	$250,000.00	318,608

Clay B. Siegall Buying and Selling Activity at Shattuck Labs

Shattuck Labs Company Overview

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.

Today's Range

Now: $4.38

$4.27

$4.73

50 Day Range

MA: $6.32

$3.90

$7.88

2 Week Range

Now: $4.38

$0.71

$8.33

Volume

347,553 shs

Average Volume

692,095 shs

Market Capitalization

$335.48 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08